Dianthus Therapeutics (DNTH) Enterprise Value (2017 - 2025)

Dianthus Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$403.5 million for Q4 2025.

• On a quarterly basis, Enterprise Value fell 47.03% year-over-year to -$403.5 million in Q4 2025; TTM through Dec 2025 was -$403.5 million, a 47.03% decrease from a year earlier, with the FY2025 full-year figure at -$403.5 million, down 47.03% from the prior year.
• Enterprise Value steadied at -$403.5 million in Q4 2025 per DNTH's latest filing, from -$401.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$25.0 million in Q1 2023 and bottomed at -$403.5 million in Q4 2025.
• The 5-year median for Enterprise Value is -$191.2 million (2021), against an average of -$212.5 million.
• Across the five-year window, Enterprise Value surged 84.04% in 2023 and slumped 1408.63% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$176.9 million in 2021, then surged by 57.33% to -$75.5 million in 2022, then tumbled by 130.12% to -$173.7 million in 2023, then plunged by 57.95% to -$274.4 million in 2024, then plunged by 47.03% to -$403.5 million in 2025.
• Per Business Quant, the three latest DNTH Enterprise Value figures stand at -$403.5 million (Q4 2025), -$401.6 million (Q3 2025), and -$257.4 million (Q2 2025).